Vidutolimod
Oropharynx Squamous Cell Carcinoma
Explore 17 assets in Oropharynx Squamous Cell Carcinoma →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Regeneron Pharmaceuticals
Modality
nucleic_acid
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
30Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04916002CT.gov A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Oropharynx Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vidutolimod (this asset) | Regeneron Pharmaceuticals | P2 | CC · 45 |
| Cetuximab | National Cancer Institute (NCI) | P1/2 | B |
| Irinotecan | AIDS Malignancy Consortium | P1/2 | B |
| e7 tcr-t cells | Christian Hinrichs | P2 | B |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P2 | CCC |
| had5-hpv vaccine | ImmunityBio, Inc. | P2 | CCC |
| Cis-Diamminedichloroplatinum Ii | ImmunityBio, Inc. | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
+23 more in the Oropharynx Squamous Cell Carcinoma cohort
Other indications for Vidutolimod
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P2/3 | CCC · 52 |
| Metastatic Melanoma | — | P2/3 | CCC · 49 |
| Lymph Node Cancer | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CetuximabNational Cancer Institute (NCI)B
- IrinotecanAIDS Malignancy ConsortiumB
- e7 tcr-t cellsChristian HinrichsB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsCCC
- had5-hpv vaccineImmunityBio, Inc.CCC
Citation
Floatz Terminal. Vidutolimod in Oropharynx Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vidutolimod-oropharynx-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →